Ho Sze Chan

Erasmus University Rotterdam — Netherlands

Medicine · Health Sciences

14h-index779citations32works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Radiopharmaceutical Chemistry and Applications(25), Neuroendocrine Tumor Research Advances(15), Medical Imaging Techniques and Applications(12), Neuroblastoma Research and Treatments(8), PARP inhibition in cancer therapy(5)

Publications32 total

Production of Astatine-211 for Translational Science in Radiotherapy (Research Performance Progress Report)
2024Open Access
Supplementary Figures 1-10; Supplemental Tables 1-6; and Supplemental Materials and Methods from Targeting PARP-1 with Alpha-Particles Is Potently Cytotoxic to Human Neuroblastoma in Preclinical Models
2023Open Access
Data from Targeting PARP-1 with Alpha-Particles Is Potently Cytotoxic to Human Neuroblastoma in Preclinical Models
2023Open Access
Data from Targeting PARP-1 with Alpha-Particles Is Potently Cytotoxic to Human Neuroblastoma in Preclinical Models
2023Open Access
Supplementary Figures 1-10; Supplemental Tables 1-6; and Supplemental Materials and Methods from Targeting PARP-1 with Alpha-Particles Is Potently Cytotoxic to Human Neuroblastoma in Preclinical Models
2023Open Access
Maintaining radiochemical purity of [177Lu]Lu-DOTA-PSMA-617 for PRRT by reducing radiolysis
Journal of Radioanalytical and Nuclear Chemistry·2019· 26 citedOpen Access
Targeting PARP-1 with Alpha-Particles Is Potently Cytotoxic to Human Neuroblastoma in Preclinical Models
Molecular Cancer Therapeutics·2019· 54 citedOpen Access
Radiochemical and analytical aspects of inter-institutional quality control measurements on radiopharmaceuticals
EJNMMI Radiopharmacy and Chemistry·2019· 24 citedOpen Access
Semi-automated system for concentrating 68Ga-eluate to obtain high molar and volume concentration of 68Ga-Radiopharmaca for preclinical applications
Nuclear Medicine and Biology·2018· 7 citedOpen Access
213-Bi-DOTATATE for Targeted Alpha Therapy in Neuroendocrine Tumours
RePub (Erasmus University, Rotterdam)·2017Open Access
In Vitro comparison of 213Bi- and 177Lu-radiation for peptide receptor radionuclide therapy
PLoS ONE·2017· 50 citedOpen Access
Improved safety and efficacy of 213Bi-DOTATATE-targeted alpha therapy of somatostatin receptor-expressing neuroendocrine tumors in mice pre-treated with l-lysine
EJNMMI Research·2016· 66 citedOpen Access
Optimizing labelling conditions of 213Bi-DOTATATE for preclinical applications of peptide receptor targeted alpha therapy
EJNMMI Radiopharmacy and Chemistry·2016· 19 citedOpen Access
Influence of tumour size on the efficacy of targeted alpha therapy with 213Bi-[DOTA0,Tyr3]-octreotate
EJNMMI Research·2016· 42 citedOpen Access
DOTATATE for preclinical applications of peptide receptor targeted alpha therapy
2016
Utilizing High-Energy γ-Photons for High-Resolution <sup>213</sup>Bi SPECT in Mice
Journal of Nuclear Medicine·2015· 36 citedOpen Access
Overview of Development and Formulation of <sup>177</sup>Lu-DOTA-TATE for PRRT
Current Radiopharmaceuticals·2015· 24 cited
L-Lysine As Kidney Protectant In Targeted Alpha Therapy With 213Bi-DOTATATE
2015
Therapeutic application of CCK2R-targeting PP-F11: influence of particle range, activity and peptide amount
EJNMMI Research·2014· 24 citedOpen Access
Determination of peptide content and purity of DOTA-peptides by metal ion titration and UPLC: an alternative method to monitor quality of DOTA-peptides
Journal of Radioanalytical and Nuclear Chemistry·2014· 11 cited
page 1 of 2Next →

Frequent Co-authors

Erik de Blois(23), Wouter A.P. Breeman(22), Mark Konijnenberg(15), Marion de Jong(10), Mehran Makvandi(8), Robert H. Mach(6), Frank Bruchertseifer(6), Jeffrey P. Norenberg(5), Hwan Lee(5), Laura N. Puentes(5), Sean W. Reilly(5), Komal S. Rathi(5), Chi-Chang Weng(5), Catherine Hou(5), Pichai Raman(5), Kuiying Xu(5), Sean Carlin(5), Roger A. Greenberg(5), Bruce Pawel(5), John M. Maris(5)